All In Biotech

Drug Trial Radar · NCT03598790

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

A Multicenter, Open-Label Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Last checked: Nov 20, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,353 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,353

Actual

Start

Sep 5, 2018

Primary completion

Nov 14, 2023

Study completion Nov 14, 2023

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Jul 26, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to evaluate the long-term safety and tolerability of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis (PSO).

Conditions

  • Chronic Plaque Psoriasis
  • Moderate to Severe Chronic Plaque Psoriasis

Interventions

  • BimekizumabDrug

    Subjects will receive bimekizumab at pre-specified time-points.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Treatment Emergent Adverse Events (TEAEs) Adjusted by Duration of Subject Exposure to Investigational Medicinal Product (IMP)Time frame: From Baseline up to 165 weeks for each study participant not entering the OLE2 Period and up to 212 weeks for participants entering OLE2 Period

Locations

189 sites in 13 countries. Site status is shown where the registry gives one.

  • Ps0014 957

    Glendale, Arizona

  • Ps0014 946

    Phoenix, Arizona

  • Ps0014 910

    Bakersfield, California

  • Ps0014 927

    Los Angeles, California

  • Ps0014 919

    San Diego, California

  • Ps0014 955

    San Diego, California

  • Ps0014 943

    San Luis Obispo, California

  • Ps0014 967

    Santa Monica, California

  • Ps0014 934

    Washington D.C., District of Columbia

  • Ps0014 909

    Boynton Beach, Florida

  • Ps0014 912

    Coral Gables, Florida

  • Ps0014 928

    Fort Myers, Florida

  • Ps0014 906

    Hollywood, Florida

  • Ps0014 907

    Miami, Florida

  • Ps0014 903

    Ocala, Florida

  • Ps0014 921

    Ormond Beach, Florida

  • Ps0014 936

    Tampa, Florida

  • Ps0014 941

    Alpharetta, Georgia

  • Ps0014 954

    Skokie, Illinois

  • Ps0014 911

    Plainfield, Indiana

  • Ps0014 900

    West Des Moines, Iowa

  • Ps0014 905

    Overland Park, Kansas

  • Ps0014 962

    Owensboro, Kentucky

  • Ps0014 922

    Baton Rouge, Louisiana

  • Ps0014 944

    New Orleans, Louisiana

  • Ps0014 940

    Beverly, Massachusetts

  • Ps0014 925

    Brighton, Massachusetts

  • Ps0014 917

    Troy, Michigan

  • Ps0014 915

    Clayton, Missouri

  • Ps0014 958

    Omaha, Nebraska

  • Ps0014 901

    Portsmouth, New Hampshire

  • Ps0014 908

    East Windsor, New Jersey

  • Ps0014 956

    Verona, New Jersey

  • Ps0014 947

    Buffalo, New York

  • Ps0014 965

    Kew Gardens, New York

  • Ps0014 913

    New York, New York

  • Ps0014 963

    Rochester, New York

  • Ps0014 961

    Rocky Mount, North Carolina

  • Ps0014 932

    Oklahoma City, Oklahoma

  • Ps0014 920

    Portland, Oregon

Showing 40 of 189 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.